Physician profile
James C Smith
NPI 1972543114
$2,543.54
in general payments reported to CMS, 2019-2025
36 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $135 · 2021: $267 · 2022: $427 · 2023: $648 · 2024: $627 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.86 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $262.15 | 2019-2025 | |
| Astellas Pharma US INC | $244.03 | 2020-2025 | Xtandi |
| Janssen Biotech, INC. | $234.68 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Celgene Corporation | $163.75 | 2021-2023 | Pomalyst, Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $162.22 | 2022-2024 | Opdualag, Opdivo |
| Amgen INC. | $141.81 | 2019-2023 | Kyprolis, Nplate, Vectibix |
| Abbvie INC. | $121.56 | 2021-2024 | |
| Stryker Corporation | $118.22 | 2025 | Flowtriever, Clottriever Bold Catheter, Ct Thrombectomy System Kit |
| Galvanize Therapeutics, INC | $116.52 | 2024 | Aliya System |
| Seagen INC. | $116.48 | 2022-2023 | Adcetris |
| Merck Sharp & Dohme LLC | $111.18 | 2019-2024 | Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.19 | 2020-2023 | Jardiance |
| Pfizer INC. | $83.75 | 2024-2025 | |
| Genentech USA, INC. | $52.17 | 2019-2024 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $48.97 | 2021-2023 | Alunbrig |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $40.26 | 2019-2024 | Lynparza |
| Rigel Pharmaceuticals, INC. | $40.16 | 2021-2023 | Rezlidhia, Tavalisse |
| Glaxosmithkline, LLC. | $39.08 | 2023-2025 | Ojjaara |
| Gilead Sciences, INC. | $30.59 | 2023 | Trodelvy |
| Daiichi Sankyo INC. | $29.69 | 2024 | Enhertu |
| Eisai INC. | $24.40 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $24.20 | 2021 | |
| Exelixis INC. | $23.18 | 2025 | Cabometyx |
| Geron Corporation | $21.50 | 2024 | Rytelo |
| Stemline Therapeutics INC. | $21.19 | 2023 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $20.07 | 2024 | |
| Genzyme Corporation | $19.65 | 2022 | |
| Karyopharm Therapeutics INC. | $19.43 | 2020 | |
| Springworks Therapeutics, INC. | $17.42 | 2024 | Ogsiveo |
| Azurity Pharmaceuticals, INC. | $16.82 | 2025 | Danziten |
| Array Biopharma INC | $16.71 | 2022 | |
| Adaptive Biotechnologies Corporation | $16.41 | 2022 | |
| Incyte Corporation | $16.36 | 2023 | Pemazyre |
| Abbott Laboratories | $15.06 | 2023 | Xience Skypoint |
| Sobi, INC | $14.68 | 2024 | |
| Emd Serono, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.